Inhibition of Ebola Virus by a Molecularly Engineered Banana Lectin.

• Egile Nagusiak: Evelyn M Covés-Datson (Egilea), Julie Dyall (Egilea), Lisa Evans DeWald (Egilea), Steven R King (Egilea), Derek Dube (Egilea), Maureen Legendre (Egilea), Elizabeth Nelson (Egilea), Kelly C Drews (Egilea), Robin Gross (Egilea), Dawn M Gerhardt (Egilea), Lisa Torzewski (Egilea), Elena Postnikova (Egilea), Janie Y Liang (Egilea), Bhupal Ban (Egilea), Jagathpala Shetty (Egilea), Lisa E Hensley (Egilea), Peter B Jahrling (Egilea), Gene G Olinger (Egilea), Judith M White (Egilea), David M Markovitz (Egilea)
• Formatua: Liburua
• Argitaratua: Public Library of Science (PLoS), 2019-07-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Ebolaviruses cause an often rapidly fatal syndrome known as Ebola virus disease (EVD), with average case fatality rates of ~50%. There is no licensed vaccine or treatment for EVD, underscoring the urgent need to develop new anti-ebolavirus agents, especially in the face of an ongoing outbreak in the...